Paxman AB (PAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Paxman AB (PAX) has a cash flow conversion efficiency ratio of -0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.98 Million ≈ $-643.87K USD) by net assets (Skr427.76 Million ≈ $46.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Paxman AB - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Paxman AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PAX current and long-term liabilities for a breakdown of total debt and financial obligations.
Paxman AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Paxman AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hwa Fong Rubber Ind Co Ltd
TW:2109
|
0.062x |
|
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
|
1.127x |
|
Cannara Biotech Inc
V:LOVE
|
0.072x |
|
Megaforce Co Ltd
TWO:3294
|
-0.004x |
|
Her Chee Industrial Co Ltd
TWO:8937
|
-0.012x |
|
Dongkuk Industries Co. Ltd
KQ:005160
|
0.085x |
|
Encounter Resources Ltd
AU:ENR
|
-0.009x |
|
Tarsons Products Limited
NSE:TARSONS
|
0.032x |
Annual Cash Flow Conversion Efficiency for Paxman AB (2017–2024)
The table below shows the annual cash flow conversion efficiency of Paxman AB from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Paxman AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr163.99 Million ≈ $17.65 Million |
Skr39.10 Million ≈ $4.21 Million |
0.238x | +87.04% |
| 2023-12-31 | Skr122.62 Million ≈ $13.20 Million |
Skr15.63 Million ≈ $1.68 Million |
0.127x | +442.03% |
| 2022-12-31 | Skr114.20 Million ≈ $12.29 Million |
Skr2.69 Million ≈ $289.06K |
0.024x | +171.39% |
| 2021-12-31 | Skr125.75 Million ≈ $13.53 Million |
Skr-4.14 Million ≈ $-445.85K |
-0.033x | +95.77% |
| 2020-12-31 | Skr10.89 Million ≈ $1.17 Million |
Skr-8.48 Million ≈ $-913.01K |
-0.779x | -768.59% |
| 2019-12-31 | Skr28.36 Million ≈ $3.05 Million |
Skr3.31 Million ≈ $355.67K |
0.117x | +639.81% |
| 2018-12-31 | Skr25.39 Million ≈ $2.73 Million |
Skr400.00K ≈ $43.05K |
0.016x | +107.24% |
| 2017-12-31 | Skr32.77 Million ≈ $3.53 Million |
Skr-7.13 Million ≈ $-767.62K |
-0.218x | -- |
About Paxman AB
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has collaborated with the University of Huddersfield and the University of Leeds to develop a wearable medical cooling device; and the National University Hospital of … Read more